At a Glance
- Company: Hansa Biopharma AB (Nasdaq Stockholm: HNSA)
- Location: Lund, Sweden
- Headline: 2025 SwedenBIO Award winner
- Focus area: Imlifidase for highly sensitized kidney transplant patients
- Next steps: FDA review process; EU phase 3 readout 2026
What happened?
Hansa Biopharma won the prestigious 2025 SwedenBIO Award, presented at the SwedenBIO Summit in Stockholm on 21 January 2026. The award recognises Hansa’s transformation of Swedish scientific excellence into global medical impact through pioneering enzyme technology enabling kidney transplantation for highly sensitized patients.
Why does it matter?
Since 2007, the SwedenBIO Award celebrates scientific progress, operational excellence and international impact. Hansa’s imlifidase, a first‑in‑class IgG‑cleaving enzyme, addresses unmet needs in transplantation while HNSA‑5487 advances for Guillain‑Barré Syndrome, positioning Sweden as a life sciences leader.
Who’s behind it?
Hansa Biopharma develops immunoglobulin‑cleaving enzymes for transplant immunology and autoimmune diseases, with operations in Europe and the US.
How was it achieved?
Judges highlighted Hansa’s strong US phase 3 data, upcoming FDA review and anticipated EU phase 3 readout, demonstrating breakthrough innovation and commercial capabilities.
What’s next?
Hansa enters 2026 with FDA review momentum and EU phase 3 results expected later this year, advancing imlifidase toward potential approvals.
What are people saying?
CEO Renée Aguiar‑Lucander: “This recognition reflects great momentum heading into 2026—powered by our strong US phase 3 data, upcoming FDA review and anticipated EU phase 3 readout.”